Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases

OBJECTIVE: Osimertinib is a third-generation, irreversible, small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that can effectively penetrate the blood brain-barrier (BBB). This study mainly explored the factors affecting the prognosis of EGFR-mutant advanced non-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Qiuyue, Xu, Yan, Zhao, Jing, Gao, Xiaoxing, Chen, Minjiang, Pan, Ruili, Zhong, Wei, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996091/
https://www.ncbi.nlm.nih.gov/pubmed/36867956
http://dx.doi.org/10.1016/j.tranon.2023.101637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996091/
https://www.ncbi.nlm.nih.gov/pubmed/36867956
http://dx.doi.org/10.1016/j.tranon.2023.101637

Ejemplares similares